Clinical Trial Update: CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CAPOX and Bevacizumab with or without primary tumor radiotherapy, plus iparomlimab and tuvonralimab, as first-line therapy f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Rectal Neoplasms Malignant | Phase 2 | Status: NOT_YET_RECRUITING